Fennec Pharmaceuticals Inc. (NASDAQ:FENC) just released its second-quarter report and things are looking bullish. Fennec Pharmaceuticals delivered a significant beat to revenue and earnings per share (EPS) expectations, hitting US$18m-11% above indicated-andUS$0.05-150% above forecasts- respectively Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

After the latest results, the six analysts covering Fennec Pharmaceuticals are now predicting revenues of US$72.9m in 2026. If met, this would reflect a huge 23% improvement in revenue compared to the last 12 months. Earnings are expected to improve, with Fennec Pharmaceuticals forecast to report a statutory profit of US$0.32 per share. Before this earnings report, the analysts had been forecasting revenues of US$69.8m and earnings per share (EPS) of US$0.26 in 2026. There's been a pretty noticeable increase in sentiment, with the analysts upgrading revenues and making a sizeable expansion in earnings per share in particular.

It will come as no surprise to learn that the analysts have increased their price target for Fennec Pharmaceuticals 13% to US$17.67on the back of these upgrades. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. The most optimistic Fennec Pharmaceuticals analyst has a price target of US$20.00 per share, while the most pessimistic values it at US$16.00. This is a very narrow spread of estimates, implying either that Fennec Pharmaceuticals is an easy company to value, or - more likely - the analysts are relying heavily on some key assumptions.

Of course, another way to look at these forecasts is to place them into context against the industry itself. The period to the end of 2026 brings more of the same, according to the analysts, with revenue forecast to display 52% growth on an annualised basis. That is in line with its 54% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 23% per year. So although Fennec Pharmaceuticals is expected to maintain its revenue growth rate, it's definitely expected to grow faster than the wider industry.

The Bottom Line

The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Fennec Pharmaceuticals following these results. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.

With that in mind, we wouldn't be too quick to come to a conclusion on Fennec Pharmaceuticals. Long-term earnings power is much more important than next year's profits. We have estimates - from multiple Fennec Pharmaceuticals analysts - going out to 2028, and you can see them free on our platform here.

Don't forget that there may still be risks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.